Special Issue

Aortic Valve Replacement: Current Clinical Practice and Future Challenges

Message from the Guest Editors

Cardiac surgery has undergone tremendous evolution in recent years, resulting in an operative mortality as low as 1%-3% in patients that underwent elective cardiac surgery. Calcified aortic valve stenosis represents the most common acquired valvular pathology; thus, aortic valve replacement (AVR) is currently the second most frequently performed cardiac surgery after isolated CABG. Besides conventional surgical AVR (SAVR) with either mechanical or biological prosthesis, the evolution of minimally invasive techniques and transcatheter procedures (TAVI, "valve in valve" procedure) paved the way for a more sophisticated treatment. However, the employment of these techniques in intermediate- as well as low-risk patients is still lacking of convincing long-term results. Undoubtedly, all these new technologies and technical advances of the current conventional prostheses enabled heart surgeons to plan and perform patient-tailored management with enhanced outcomes, quality of services, and quality of life. Our aim is to provide the readers with the cuttingedge and up-to-date advances, as well as to discuss the future challenges in this topic.

Guest Editors

Dr. Kyriakos Spiliopoulos

Department of Cardiothoracic Surgery, University of Thessaly, Biopolis, 41110 Larissa, Greece

Dr. Andrew Xanthopoulos

Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece

Deadline for manuscript submissions

closed (25 June 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/219866

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

